MedPath

Phase 3 study of cetirizine dry syrup in children suffering from perennial allergic rhinitis (Comparative study)

Phase 3
Conditions
Perennial Allergic Rhinitis
Registration Number
JPRN-jRCT2080220122
Lead Sponsor
GlaxoSmithKline K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Not specified
Target Recruitment
286
Inclusion Criteria

Age: 3 to 14, Children with perennial allergic rhinitis, Patients eligible for evaluation of nasal symptom, etc.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in the total nasal symptom score, safety, etc
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath